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Alopecia areata (AA) is a common cause of non scarring alo-
pecia that occurs in a patchy, conﬂuent or diffuse pattern. It
may involve loss of hair from some or all areas of the body,
usually from the scalp (Odom, 2006). In 1–2% of cases, the
condition can spread to the entire scalp (Alopecia totalis) or
to the entire epidermis (Alopecia universalis). AA has a re-
ported incidence of 0.1–0.2% with a lifetime risk of 1.7% with
men and women being affected equally (Safavi et al., 1995).
Sharma et al. in their decade long prospective study observed
an incidence of 0.7% among new dermatology outpatients
(Sharma et al., 1996). The etiology of AA has eluded investiga-
tors for years and therefore a multitude of associations have
been proposed by researchers in the ﬁeld of trichology. One
of the strongest associations is with autoimmunity (McDonaghFigure 1 Phasesand Tazi-Ahnini, 2002; Hordinsky and Ericson, 2004). This
view has been supported by the occurrence of AA in associa-
tion with other autoimmune disorders like vitiligo, lichen pla-
nus, morphea, atopic dermatitis, Hashimoto’s thyroiditis,
perinicious anemia and diabetes mellitus (Brenner, 1979).
More recently, it has been reported that there is a high preva-
lence of mood, adjustment, depressive and anxiety disorders in
patients with AA (Ruiz-Doblado et al., 2003). This element of
psychiatric morbidity has widely been purported to be both, a
cause and effect of AA. A multipronged approach is therefore
warranted in the management of such patients. Though corti-
costeroids have been the mainstay in therapy, a wide array of
evidence based therapies have come into fore for management
of AA. The present study attempts to systematically review the
various aspects in the natural history of alopecia areata and
the pros and cons in the different treatment modalities.of hair growth.
Figure 2 Multifactorial etiology of alopecia areata.
Figure 3 Localised patch of alopecia areata on scalp.
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Hair follicle growth occurs in cycles (Fig. 1). Each cycle consists
of a long growing phase (anagen), a short transitional phase
(catagen) and a short resting phase (telogen). At the end of
the resting phase, the hair falls out (exogen) and a new hair
starts growing in the follicle beginning the cycle again. There
are considerable variations in the length of the three phases,
with the duration of the anagen determining the type of hair
produced, particularly its length. Normally about 100 strands
of hair reach the end of their resting phase each day and fallout
(Trueb, 2010). Hair loss in non scarring alopecias, including
alopecia areata essentially represents a disorder of hair follicle
cycling (Paus, 1996). It is believed that in AA, an as yet uniden-
tiﬁed trigger stimulates an autoimmune lymphocytic attack on
the hair bulb. This inﬂammation is speciﬁc for anagen hairs
and causes anagen arrest. A disruption of the growing phase,
that is anagen arrest, causes abnormal loss of anagen hairs (ana-
gen efﬂuvium), clinically recognized as dystrophic anagen hair
with tapered proximal ends and lack of root sheaths. A related
but distinct entity observed very frequently in women is ‘telogen
efﬂuvium’. This is an umbrella term inclusive of conditions
wherein the affected hairs undergo an abrupt conversion from
anagen to telogen (anagen release), clinically seen as localized
shedding of hair in the telogen and morphologically identiﬁed
as hair with a depigmented bulb (Wasserman et al., 2007).
3. Etiopathogenesis
The etiology of AA has experienced considerable drift over the
years and different schools of thought have assigned varied eti-
ologies to the condition (Fig. 2). A viral etiology was proposed
in the late 1970s but subsequent articles have demonstrated no
connection (Tosti et al., 1996). A genetic study by Yang et al.
found that 8.4% of the patients had a positive family history of
AA, suggesting a polygenic additive mode of inheritance
(Yang et al., 2004). It has now been widely postulated that
AA is an organ-speciﬁc autoimmune disease with genetic pre-
disposition and an environmental trigger (McMichael, 1997;McDonagh and Tazi-Ahnini, 2002). An association between
AA and human leukocyte antigen (HLA) has been demon-
strated. Kavak et al. reported patients with AA had HLA-
A1, HLA-B62, HLA-DQ1, and HLADQ3 (Ay Se et al.,
2000). Recently, in the United States, Barahmani et al. demon-
strated that a non-HLA molecule including the major histo-
compatibility complex class I chain-related gene A (MICA)
is associated with AA. It could be a potential candidate gene
and part of an extended HLA haplotype that may contribute
to susceptibility and severity of this entity (Barahmani et al.,
2006). HLA class I molecules are expressed on virtually all
nucleated cells and platelets and present antigens to CD8+
T cells. HLA class II molecules have three main subclasses
(DR, DQ, and DP); they are found on speciﬁc immune cells,
including B cells, activated T cells, macrophages, keratino-
cytes, and dendritic cell and present peptides to CD4+ T cells.
Because class II molecules are associated with antigen presen-
tation, many studies have focused on this area of the HLA
molecule (Mari, 2004).
These associations with HLA-DR and HLA-DQ suggest a
role for T cells in this disease as well as autoimmunity. Patients
with AA have an increased frequency of autoantibodies to follic-
ular structures; however, there is little consistency in which follic-
ular structures are labeled by the antibodies (Gilhar and Kalish,
2006). Other diseases that are reported to be associated with AA
are at higher rate than the normal population. They are atopic
dermatitis, vitiligo, thyroid disease, and Down’s syndrome
(Tan et al., 2002). Most of the research in the ﬁeld of AA thus
demonstrates a strong case for the implication of autoimmunity
in the etiopathogenesis. Other potential offenders proposed in
the causation of AA are psychologic stress, anemia, parasitic
infestations, hypothyroidism, hyperthyroidism and diabetes.
3.1. Animal models in the understanding of pathogenesis
The Dundee experimental bald rat (DEBR) and the C3H/HeJ
mouse are well-established animal models for alopecia areata
and can be used for the study of genetic aspects, pathogenesis
and therapy of the disease. In C3H/HeJ mice alopecia areata
can be experimentally induced by grafting lesional skin from
an affected mouse to a histocompatible recipient which offers
the possibility to study the inﬂuence of various factors on the
development of the disease. Studies on the C3H/HeJ mouse
and the DEBR have corroborated the concept that alopecia
areata is a T-cell mediated autoimmune disease and various
steps and aspects of the pathogenesis have been elucidated.
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developed such as inhibition of lymphocyte-homing by an
anti-CD44v10 antibody, or inhibition of costimulation by
monoclonal antibodies (Freyschmidt-Paul et al., 2004).
Animal models have also suggested a role of vitamin A in
the regulation of both the hair cycle and immune response to
alter the progression of AA. Gene array in graft-induced
C3H/HeJ mice revealed that genes involved in retinoic acid
(RA) synthesis were increased, whereas RA degradation genes
were decreased in AA compared with sham controls. RA levels
were also increased in C3H/HeJ mice with AA. C3H/HeJ mice
were fed a puriﬁed diet containing one of the four levels of die-
tary vitamin A or an unpuriﬁed diet 2 weeks before grafting
and disease progression followed. High vitamin A accelerated
AA, whereas mice that were not fed vitamin A had more severe
disease by the end of the study. More hair follicles were in ana-
gen in mice fed with high vitamin A. Both the number and
localization of granzyme B-positive cells were altered by vita-
min A. IFNc was the lowest and IL13 highest in mice fed with
high vitamin A. Other cytokines were reduced and chemokines
increased as the disease progressed (Duncan et al., 2013).
3.2. Psychological factors
Some studies have suggested that emotional stress contributes
to the appearance of alopecia areata, given the observation
that emotional trauma precedes the process (Baker, 1987) to-
gether with the high prevalence of psychological disorders
occurring in these patients (Colon et al., 1991). While, on the
contrary, other studies have demonstrated that there is no par-
ticipation of emotional phenomena in the development of alo-
pecia areata (van der Steen et al., 1992).
A possible explanation of the pathogenic mechanisms pro-
voked by emotional conditions lies in the production of neu-
romediators capable of interfering in the immunity. Some
studies have revealed a decrease in the expression of calcitonin
gene related peptide (CGRP) and substance P in the scalp of
alopecia areata patients (Hordinsky et al., 1995a,b). CGRP
has an anti-inﬂammatory action, (Raud et al., 1991) and its de-
crease in alopecia areata could favor the characteristic follicu-
lar inﬂammatory phenomena. Substance P is capable of
inducing hair growth in mice (Paus et al., 1994) and its de-
crease in alopecia areata could be a contributing factor to
the reduced proliferation of pilar follicles.
4. Clinical features
The diagnosis of AA is essentially made on clinical grounds.
Age at onset, duration and progression of disease, personal
and family history of atopy, family history of similar disease
with special reference to autoimmune disease and other sys-
temic complaints are noted in detail. Routine investigations like
complete hemogram, anemia panel, erythrocyte sedimentation
rate, thyroid function tests, serum calcium, serum proteins,
etc. should be carried out to arrive at a speciﬁc diagnosis. Skin
biopsy and autoimmune panel may be performed in selected
cases. Alopecia areata most commonly manifests as a sudden
loss of hair in localized areas. The lesion is usually a round or
oval patch of alopecia and may be solitary (Alopecia Areata
monolocularis) or numerous (Alopecia Areata multilocularis).
The patch of alopecia usually has a distinct border where nor-mal hair demarcates the periphery of the lesion (Fig. 3). The
scalp is the most common site affected by AA (90%) Tan et
al. (2002) andCamacho (1997). Scalp and body hair such as eye-
brows, eyelashes, beard, underarm hair, and pubic hair may be
affected (Alopecia Totalis), as well as the entire body (Alopecia
Universalis). The ophiasis pattern refers to a severe form of AA
extending along the posterior occipital and temporal scalp mar-
gins. The affected skin appears normal with no grossly evident
epidermal alterations such as scaling or follicular abnormalities
(Diana Draelos, 2007). In all forms ‘‘exclamation point hairs’’
are found, that become narrower along the length of the strand
closer to the base may be seen within or around the areas of alo-
pecia (Cline, 1988). Upon regrowth, hair often initially lack pig-
ment resulting in blonde or white hair (Finner, 2011). Nail
changes can be seen in a portion of patients (10–66%) of AA.
Small shallow pits (30%) up to trachyonychia (sandpaper nails;
10%) are typical, rarely other changes can also be seen. A red-
spotted lunula and periungual erythema have been postulated
as a sign of acute nail involvement (Olsen, 2003).
4.1. Quantitating hair loss
Hair pull tests conducted at the periphery of the lesion may be
correlated with disease activity and also assist in determining
the etiology of alopecia. A few clinical tests are presented
below:
 The pull test: this test helps to evaluate diffuse scalp hair loss.
Gentle traction is exerted on a group of hair (about 40–60) on
three different areas of the scalp. The number of extracted
hairs is counted and examined under a microscope. Nor-
mally, <3 hairs per area should come out with each pull. If
>10 hairs are obtained, the pull test is considered positive.
 The pluck test: In this test, the individual pulls hair out ‘‘by
the roots.’’ The root of the plucked hair is examined under a
microscope to determine the phase of growth and used to
diagnose a defect of telogen, anagen, or systemic disease.
Telogen hairs are hairs that have tiny bulbs without sheaths
at their roots. Telogen efﬂuvium shows an increased per-
centage of hairs upon examination. Anagen hairs are hairs
that have sheaths attached to their roots. Anagen efﬂuvium
shows a decrease in telogen-phase hairs and an increased
number of broken hairs.
 Scalp biopsy: This test is done when alopecia is present, but
the diagnosis is unsure. The biopsy allows for differing
between scarring and nonscarring forms in case there is clin-
ical distinction is difﬁcult. Hair samples are taken from areas
of inﬂammation, usually around the border of the bald patch.
 Daily hair counts: This is normally done when the pull test is
negative. It is done by counting the number of hairs lost. The
hair that should be counted are the hairs from the ﬁrst morn-
ing combing or duringwashing. The hair is collected in a clear
plastic bag for 14 days. The strands are recorded. If the hair
count is >100/day, it is considered abnormal except after
shampooing, where hair counts will be up 250 and be normal.
 Trichoscopy: Trichoscopy is a non-invasive method of hair
and scalp evaluation. The test may be performed with the
use of a hadheld dermoscope or a videodermoscope. In alo-
pecia areata trichoscopy shows regularly distributed ‘‘yel-
low dots’’ (hyperkeratotic plugs), micro-eclamation mark
hairs, and ‘‘black dots’’ (destroyed hairs in the hair follicle
opening.
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ting or trachyonychia (Olsen et al., 2004). Stigmata of organ
speciﬁc autoimmunity may be present on systemic
examination.
4.2. Gauging severity of disease
Researchers have devised a clinical scale in order to assess the
severity of AA (Ay Se et al., 2000), presented as follows:
1 Mild: Three or less patches of alopecia with a widest diam-
eter of <3 cm or disease limited to eyelashes and eyebrows.
2 Moderate: Existence of more than three patches of alopecia
or a patch greater than 3 cm at the widest diameter without
alopecia totalis or universalis.
3 Severe: Alopecia totalis or alopecia universalis.
4 Ophiasis: Severe form in which loss of hair occurs in the
shape of a wave at the circumference of the head (described
above).
The National Alopecia Areata Foundation working com-
mittee has devised ‘‘Severity of Alopecia Tool score’’ (SALT
score) Price and Gummer, 1989. Scalp is divided into four areas
namely, Vertex – 40% (0.4) of scalp surface area; right proﬁle of
scalp – 18% (0.18) of scalp surface area; left proﬁle of scalp –
18% (0.18) of scalp surface area; Posterior aspect of scalp –
24% (0.24) of scalp surface area. Percentage of hair loss in
any of these areas is percentage of hair loss multiplied by per-
cent surface area of the scalp in that area. SALT score is the
sum of percentage of hair loss in all above mentioned areas.
5. Differential diagnosis
Though alopecia areata is a form of non scarring alopecia, it is
sometimes confused with different varieties of scarring alope-
cia as well. This is also because many alopecia types are bipha-
sic in their natural history. The ﬁrst step, therefore is to
distinguish between scarring and non scarring alopecias. Scar-Figure 4 Swarm of bees’ appearance of the inﬂammatory
inﬁltrate around terminal hair follicles in alopecia areata. (H&E
stain).ring alopecias have loss of follicular ostia, or atrophy. Clinical
inﬂammation is frequently, but not always, present. Histologic
inﬂammation may be present. Ultimately, histologic conﬁrma-
tion is the best method to conﬁrm the presence of a ﬁbrosing/
scarring process with loss of hair follicles. A few entities in
scarring alopecias are Lichen planopilaris, Central centrifugal
cicatricial alopecia, Pseudopelade, Discoid lupus and Traction
alopecia. The main confounders in diagnosis are the other
varieties of non scarring alopecias. They are:
 Trichotillomania: this condition probably causes most con-
fusion and it is possible that it coexists with alopecia areata
in some cases. The incomplete nature of the hair loss in
trichotillomania and the fact that the broken hairs are
ﬁrmly anchored in the scalp (i.e. they remain in the growing
phase, anagen, unlike exclamation mark hairs) are distin-
guishing features.
 Tinea capitis: the scalp is inﬂamed in tinea capitis and there
is often scaling but the signs may be subtle.
 Early scarring alopecia.
 Telogen efﬂuvium.
 Anagen efﬂuvium (drug-induced) may mimic diffuse alope-
cia areata.
 Systemic lupus erythematosus.
 Secondary syphilis.
 Loose anagen hair syndrome: This is a disorder of abnormal
anagen hair anchorage. It is commonly found in children
and has an autosomal dominant inheritance (Lew, 2009).
 ADTA: Acute diffuse and total alopecia (ADTA) is a new
subtype of alopecia areata with favorable prognosis. ADTA
has been reported to have a short clinical course ranging
from acute hair loss to total baldness, followed by rapid
recovery, sometimes even without treatment (Garcia-Her-
nandez, 2000).
 SISAPHO: This is an unusual form of Alopecia, in which a
band-like pattern is found on the frontal hairline. This can
be clinically confused with frontal ﬁbrosing alopecia. The
opposite of ophiasis type, where hairs are lost centrally
and spared at the margins of the scalp, is called sisiapho.
It may mimic androgenetic alopecia (Ragunatha et al.,
2008).
Raunatha et al. in their case report have demonstrated
infantile scurvy also, as a cause of diffuse non scarring alopecia
of the scalp (Whiting, 2003).
6. Histopathology
The histopathologic features of alopecia areata depend on
the stage of the current episode and do not vary with the
age, sex or race of the patient (Igarashi et al., 1981). In
the acute stage, terminal hairs are surrounded by bulbar lym-
phocytes (‘swarm of bees’) (Fig. 4). In the subacute stage, de-
creased anagen and increased catagen and telogen hairs are
characteristically found. In the chronic stage, decreased ter-
minal and increased miniaturized hairs are found, with vari-
able inﬂammation. Immunoﬂuorescence studies have shown
deposits of C3, IgG, and IgM along the basement membrane
of the inferior part of the hair follicle (Shimmer and Parker,
2001). During recovery, increasing numbers of terminal ana-
gen hairs from regrowth of miniaturized hairs and a lack of
inﬂammation are noted. Alopecia areata should histologically
Figure 5 Algorithm for management of Alopecia areata in different age groups. (*Adapted with permission from the Editor, J. Am.
Acad. Dermatol. 2010;62:191–202).
42 S.S. Amin, S. Sachdevabe suspected when high percentages of telogen hair or minia-
turized hair are present, even in the absence of a peribulbar
lymphocytic inﬁltrate. The histopathology of the lesion in
ADTA reveals inﬁltration of mononuclear cells around the
hair follicles and prominent pigment incontinence (Garcia-
Hernandez, 2000).
7. Management
Management of patients with alopecia areata is a challenging
task as a number of risk factors have been implicated in its eti-
ology. No deﬁnitive cure has been established, and treatment
has focused mainly on containing disease activity.
7.1. Glucocorticoids
Topical and intralesional steroids have been the mainstay of
therapy, and have been used as ﬁrst line agents for the manage-
ment of the same. Glucocorticoids have been harnessed for
their overarching anti-inﬂammatory effects for AA (Ross
and Shapiro, 2005).
7.1.1. Intralesional corticosteroids
For circumscribed AA involving less than 50% of the scalp,
intralesional corticosteroids are the ﬁrst-line approach (Mada-
ni and Shapiro, 2000). Triamcinolone acetonide in a concen-
tration of 10 mg/ml is administered using a 0.5-inch long 30-
gauge needle in multiple 0.1 mL injections approximately
1 cm apart (Pascher et al., 1970). Initial results of intralesionaltreatment are often seen in 1–2 months. Additional treatments
are repeated every 4–6 weeks.
7.1.2. Topical corticosteroids
Several forms of topical corticosteroids have been reported to
exhibit varying levels of efﬁcacy in AA. Some of the topical
therapies have included ﬂuocinolone acetonide cream, ﬂuocin-
olone scalp gel, betamethasone valerate lotion and clobetasol
propionate ointment (Tosti et al., 2003; Camacho, 1997). They
remain a very good option in children because of their painless
application and wide safety margin.
7.1.3. Systemic corticosteroids
Systemic corticosteroids do not constitute the ﬁrst line treat-
ment for alopecia areata because of their extensive side effect
proﬁle. The dosages necessary to maintain hair regrowth in
AA are between 30 and 150 mg daily (Burton and Shuster,
1975). Treatment course can range from 1 to 6 months, but
prolonged courses should be avoided secondary to the numer-
ous side effects of these drugs especially when children are trea-
ted. Systemic steroids are thus not preferred in the treatment of
alopecia areata except for some cases as a short course only. Its
side effect proﬁle in conjunction with the long-term treatment
requirements and high relapse rates make systemic corticoste-
roids a more limited option. Friedli et al. (1998) have also re-
ported successful therapy with pulsed methylprednisolone
(250 mg IV twice daily for three consecutive days) in patchy
AA. Contraindications and side effects should however be dis-
cussed at length with patients considered for this therapy.
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To avoid the side effects of daily steroids, pulse therapy was
conceived.In a study conducted by Pasricha et al., betametha-
sone oral mini-pulse therapy is a convenient and fairly effective
treatment modality for extensive alopecia areata (Pasricha and
Kumrah, 1996). However, it is proposed that randomized con-
trolled trials with standard therapies on a larger number of pa-
tients are required to give more insight into the efﬁcacy and
safety of oral mini-pulse therapy for extensive alopecia areata.
Oral mini-pulse therapy (OMP) with corticosteroids has been
successfully used for the treatment of alopecia areata with min-
imal side effects. Persistent hiccups is a rare complication of
oral and intravenous corticosteroid therapy (Dickerman and
Jaikumar, 2001).
7.2. Minoxidil
First introduced as an antihypertensive agent, its side effect of
hypertrichosis led to its use as treatment for various forms of
alopecia. Minoxidil directly affects follicles by stimulating pro-
liferation at the base of the bulb and differentiation above the
dermal papilla, independent of its vascular inﬂuences (Fiedler
et al., 1990). Minoxidil has shown considerable results in the
management of AA and it is believed that patients resistant
to minoxidil treatment often suffer from severe AA, AT or
AU (Buhl, 1991; Fransway and Muller, 1988). Combination
therapy of minoxidil 5% lotion and anthralin have been docu-
mented to show better results by few authors (Price, 1987).
7.3. Anthralin
Anthralin exerts its effect through its irritant contact proper-
ties. It also acts through its immunosuppressive and anti-
inﬂammatory properties via the generation of free radicals
(Madani and Shapiro, 2000). Patients are instructed to apply
0.5–1% anthralin cream to bare areas for 20–30 min daily over
2 weeks, gradually increasing daily exposure until low-grade
erythema and pruritus develops, which when once achieved
is continued for 3–6 months (Ross and Shapiro, 2005). It is be-
lieved to be a suitable agent for children under 10 years of age
(Thappa and Vijayikumar, 2001). Adverse effects include scal-
ing, staining of treated skin and fabrics, folliculitis, and regio-
nal lymphadenopathy.
7.4. Topical immunomodulators
Topical immunotherapy relies on inciting an allergic contact
dermatitis (ACD) by applying potent contact allergens to the
affected skin. It is believed that contact sensitizers act through
immunomodulation of the skin and its appendages at several
different points. Dinitrochlorobenzene (DNCB) was the ﬁrst
sensitizer used for the treatment of AA (Rosenberg and Drake,
1976). Other contact sensitizers used in alopecia areata are di-
phenyl-cyclo-propenone (DPCP) and squaric acid dibutyl ester
(SADBE). The only disadvantage of DNCB is its mutagenicity
by Ames test. DNCB was however found to be non-carcino-
genic when fed in large doses in rats, mice, guinea pigs and
man. Happle and Echternacht (1977), had a good response
with DNCB. Inosiplex, a synthetic drug that acts as an immu-
nomodulating agent was used recently in cases of alopecia to-
talis and cell mediated immunodeﬁciency states withsatisfactory results (Galbraith, 1984). Adverse effects of topical
immunotherapy include pruritus, mild erythema, scaling, and
postauricular lymphadenopathy. Reported undesired side ef-
fects include contact urticaria, postinﬂammatory hyper- and
hypo-pigmentation, erythema mutliforme, facial or eyelid ede-
ma, fever, ﬂulike symptoms, anaphylaxis,‘‘dyschromia in con-
fetti,’’ and vitiligo.
7.5. PUVA
The use of PUVA (psoralen plus ultraviolet light A) is based
on the concept that the mononuclear cells and Langerhans
cells that surround the affected hair follicles may play a direct
pathogenic role and that PUVA therapy can eradicate this
inﬂammatory cell inﬁltrate. Recently, Whitmont did a study
with 8-methoxypsoralen (8-MOP) (oral dose-0.5 mg/ kg) plus
UVA radiation at 1 J per square cm (J/cm2) and have demon-
strated complete hair regrowth in patients with AA totalis
(53%) and AA universalis (55%) and a low relapse rate among
these patients (21%) within a long period of follow up (means
5.2 years) Whitmont and Cooper, 2003. In 2005, Mohamed
et al. did a large study (124 patients with AA and 25 patients
with AA totalis or universalis) (Mohamed et al., 2005). They
used topical 8-MOP plus UVA radiancy at higher doses (8–
42 J/cm2) and they found that 85% of patients from the AA
group had good or excellent response to the treatment, and
14 patients from AA U group had 50% hair regrowth. Side ef-
fects included slight erythema and painful burning in patients
who did not protect their scalp from sunlight after PUVA
exposure. Recurrence of hair loss was noted in eight cases after
a period of 10 months to 2 years of treatment.
The relatively simple procedure of PUVASOL therapy (Lo-
cal and systemic) because of good availability of solar radia-
tion, negligible side effects, encouraging results and non-
availability of various other procedures and frequent treatment
failures with these treatment schedules makes this procedure
better suited in the tropics. (Sharma et al., 1990)
7.6. Cyclosporine A (CsA)
Cyclosporine A is a common antimetabolite drug used in post-
transplantation patients which exerts its effect via inhibition of
T-cell activation. A common cutaneous side effect is hypertri-
chosis, which occurs in approximately 80% of patients, possi-
bly as a result of prolongation of the anagen phase of the hair
cycle. It also decreases the perifollicular lymphocytic inﬁl-
trates, particularly the mean number of helper T cells (Taylor
et al., 1993) Successful use of systemic CsA in patients with AA
has been conﬂicting as it is a nephrotoxic, hepatotoxic drug, it
also causes gingival hyperplasia, headaches, tremors, and
hyperlipidemia (Gupta et al., 1990).
7.7. Tacrolimus
Tacrolimus is a topical calcineurin inhibitor that inhibits tran-
scription following T-cell activation of several cytokines
including interleukin-2, interferon-and tumor necrosis factor
(Lawrence, 1998). Yamamoto et al. reported in their ﬁndings
that tacrolimus stimulated hair growth in mice (Yamamoto
et al., 1994) although subsequent studies showed conﬂicting re-
sults (Jiang et al., 1995).
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Sulfasalazine is believed to be a good alternative treatment for
alopecia areata because of its good efﬁcacy, good adverse
event proﬁle and steroid sparing nature. The drug has immu-
nosuppressive and immunomodulatory effects, including the
inhibition of inﬂammatory cell chemotaxis, and cytokine and
antibody production and similar to cyclosporine, sulfasalazine
has been shown to inhibit the release of interleukin 2 (Ellis
et al., 2002). In a study on treatment of persistent alopecia are-
ata with sulfasalazine. thirty-nine patients with persistent alo-
pecia areata received 3 g of oral sulfasalazine for months, and
terminal hair regrowth was quantiﬁed as no response, moder-
ate response, or good response. A good response occurred in
10 of the 39 patients (25.6%), a moderate response in 12
(30.7%), and a poor or no response in 17 (43.5%) AU Rashidi
and Mahd, 2008.
7.9. Mesotherapy
Mesotherapy employs multiple injections of pharmaceutical
and homeopathic medications, plant extracts, vitamins, and
other ingredients into the target tissue. However, this is expen-
sive and not effective, thereby precluding its widespread use.
7.10. Biological therapy
These medications synthesized from recombinant proteins re-
duce the pathogenic T cells, inhibit T-cell activation and inhi-
bit inﬂammatory cytokines, suggesting a potential role in the
treatment of AA. Etanercept is a biological agent and a fusion
protein receptor consisting of two human TNF receptors and
Fc domain of human immunoglobulin G1. Strober et al.
administered 50 mg of etanercept twice weekly to patients with
moderate to severe AA. They however observed no signiﬁcant
hair regrowth after 24 weeks of treatment (Strober et al.,
2005). Studies with other biological agents in the treatment
of AA are still underway. In cases where all the treatments fail,
other options that have been reported for AA are hair trans-
plant, but recently it has only been performed in eyebrows with
good results. Another alternative is micropigmentation, also
known as tattoo; it has been used esthetically to camouﬂage
various medical conditions related to dermatology.
Fig. 5 illustrates a suggested protocol for stepwise manage-
ment of Alopecia areata.
8. Conclusion
Alopecia areata has a great impact on the appearance and psy-
che of the afﬂicted individual. Moreover, no uniformly
dependable treatment is known. Corticosteroids have shown
promising results and are time tested drugs in management
over the years. Other treatments that have been used with
some success include: minoxidil, anthralin, DNCB, SADBE,
PUVA, cyclosporine. With each treatment, side effects and
cosmetically acceptable improvement must be considered. Sup-
port mechanisms in the form of local support groups should be
formed in order to provide counseling for the affected patients
and allay their psychiatric comorbidities.Source of funding
None.
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